Literature DB >> 7020837

Clinical biochemistry of muscular dystrophy.

R J Pennington.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7020837     DOI： 10.1093/oxfordjournals.bmb.a071625

Source DB:  PubMed          Journal:  Br Med Bull        ISSN： 0007-1420            Impact factor:   4.291


× No keyword cloud information.
  5 in total

1.  Use of the intact mouse skeletal-muscle preparation for metabolic studies. Evaluation of the model.

Authors:  E van Breda; H A Keizer; J F Glatz; P Geurten
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

2.  Effect of inhibitors of arachidonic acid metabolism on efflux of intracellular enzymes from skeletal muscle following experimental damage.

Authors:  M J Jackson; A J Wagenmakers; R H Edwards
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

3.  Duchenne muscular dystrophy presenting with failure to thrive.

Authors:  R Rapisarda; F Muntoni; P Gobbi; V Dubowitz
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

4.  Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Nadia Milad; Zoe White; Arash Y Tehrani; Stephanie Sellers; Fabio M V Rossi; Pascal Bernatchez
Journal:  Skelet Muscle       Date:  2017-09-12       Impact factor: 4.912

5.  Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

Authors:  Zoe White; Nadia Milad; Arash Y Tehrani; William Wei-Han Chen; Graham Donen; Stephanie L Sellers; Pascal Bernatchez
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.